- Conditions
- High-Risk Percutaneous Coronary Intervention (High-risk PCI)
- Interventions
- Elevate, Impella
- Device
- Lead sponsor
- Magenta Medical Ltd.
- Industry
- Eligibility
- 18 Years to 88 Years
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 23 more
Clinical trials in Nashville, Tennessee
This page shows live ClinicalTrials.gov search results for Nashville, Tennessee, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in Nashville
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Cystic Fibrosis
- Interventions
- VX-121/TEZ/D-IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 822 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more
- Conditions
- Early Breast Cancer
- Interventions
- Ribociclib, Endocrine Therapy (ET)
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 5,101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more
- Conditions
- Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Locally Advanced Unresectable Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute LAO
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 26
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 19 more
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 895 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 26
- States / cities
- Hot Springs, Arkansas • Springdale, Arkansas • Long Beach, California + 22 more
- Conditions
- Migraine
- Interventions
- ASY202, Placebo
- Combination Product
- Lead sponsor
- Aspeya, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Lemon Grove, California • Walnut Creek, California + 16 more
- Conditions
- Non-Small-Cell Lung
- Interventions
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Placebo Comparator, Nab-paclitaxel, Pemetrexed, Carboplatin, Cisplatin, Gemcitabine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Los Angeles, California • Orange, California + 18 more
- Conditions
- Colorectal Cancer
- Interventions
- Telisotuzumab Adizutecan, Standard of Care
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 22
- States / cities
- Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more
- Conditions
- Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
- Interventions
- ION440, Sham procedure
- Drug · Procedure
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 65 Years · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 8
- States / cities
- San Diego, California • Aurora, Colorado • Baltimore, Maryland + 5 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Ivonescimab Injection, Pembrolizumab Injection
- Biological
- Lead sponsor
- Summit Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 61 more
- Conditions
- Oropharyngeal Carcinoma (OPC)
- Interventions
- CRB-701, capcitabine, Cetuximab (EGFR inhibitor), Docetaxel
- Drug
- Lead sponsor
- Corbus Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 38
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Duarte, California + 32 more
- Conditions
- Lymphoma, Mantle Cell
- Interventions
- Acalabrutinib, Bendamustine, Rituximab, Placebo
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 635 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Downey, California • Santa Monica, California + 27 more